Industry Daily Summary
Industry Daily Summary: What Happened on October 4, 2026
Brenntag gets global rights to dsm-firmenich’s biopharma vitamins
Eight GMP-grade products will be marketed for biologics, vaccines and cell therapies.
Today in brief
Brenntag Pharma will exclusively distribute dsm-firmenich’s Biond vitamin portfolio worldwide for biopharmaceutical manufacturing.1 The deal continues a relationship between the companies that has lasted more than 30 years.1
Eight vitamins for biopharma manufacturing
The long-term partnership covers North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific.1 The vitamins are intended for cell culture and feed media, and for upstream processing to make biologics, vaccines and cell therapies.1
The products will be sold in several pack sizes under the BYPHARM powered by Biond name.1